Antiangiogenic Therapy in Gastroesophageal Cancer

Publication date: June 2017
Source:Hematology/Oncology Clinics of North America, Volume 31, Issue 3
Author(s): Zhaohui Jin, Harry H. Yoon

Teaser

Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-naïve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus. Promising ongoing clinical investigations include the combination of antiangiogenesis therapy with immune checkpoint inhibition and anti–human epidermal growth factor receptor 2 therapy.


http://ift.tt/2pDOzPo